Developmental pharmacology and therapeutics of piperacillin in gram-negative infections.

Abstract

Twenty children ranging in age from 1 week to 19 years with documented or suspected bacterial infections arising outside the central nervous system were studied. Pharmacokinetic analysis was possible in 15 children; 8 after the first dose, 6 during steady-state conditions, and 4 on both occasions. Data were obtained utilizing noncompartmental pharmacokinetic methods. Peak piperacillin serum concentrations ranged from 51 to 232 mg/l and correlated directly (r = 0.75) with the dose administered. In children with normal renal function, there was an age-dependent decrease in elimination half-life and apparent steady-state volume of distribution, whereas plasma clearance increased logarithmically. All but 1 child responded favorably to piperacillin therapy, and 1 child with a urinary tract infection relapsed 10 days after discontinuation of the therapy. Although improved clinically, piperacillin monotherapy failed to eradicate pathogens in 2 children. No adverse clinical or biochemical effects were observed in any child.

• Authors: M D Reed, C M Myers, T S Yamashita, J L Blumer
• Journal: Developmental pharmacology and therapeutics (Dev Pharmacol Ther) Vol. 9 Issue 2 Pg. 102-14 ( 1986) ISSN: 0379-8305 [Print] Switzerland
• PMID: 3956344 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Piperacillin

Topics

• Adolescent
• Adult
• Aging
• Bacterial Infections (drug therapy, microbiology)
• Child
• Child, Preschool
• Female
• Gram-Negative Bacteria (drug effects)
• Humans
• Infant
• Kinetics
• Male
• Models, Biological
• Piperacillin (pharmacology, therapeutic use, urine)
• Urinary Tract Infections (drug therapy, microbiology)